Analysts See $0.42 EPS for CONMED Corporation (CNMD)

July 17, 2017 - By Peter Erickson

 Analysts See $0.42 EPS for CONMED Corporation (CNMD)
Investors sentiment increased to 0.97 in 2016 Q4. Its up 0.12, from 0.85 in 2016Q3. It improved, as 12 investors sold CONMED Corporation shares while 48 reduced holdings. 17 funds opened positions while 41 raised stakes. 26.92 million shares or 2.31% less from 27.56 million shares in 2016Q3 were reported.
Jpmorgan Chase And holds 0% or 72,769 shares in its portfolio. Citadel Advisors Limited Liability Corp has invested 0% in CONMED Corporation (NASDAQ:CNMD). Geode Capital Limited Company holds 193,708 shares. Arizona State Retirement System holds 0.01% or 12,703 shares. Parametric Associate Limited Liability Corp has invested 0% of its portfolio in CONMED Corporation (NASDAQ:CNMD). 10,527 are held by First Tru Advsr Ltd Partnership. Credit Suisse Ag reported 30,828 shares. Pinebridge Invs Limited Partnership has invested 0.02% of its portfolio in CONMED Corporation (NASDAQ:CNMD). Camber Management Ltd owns 750,000 shares or 1.73% of their US portfolio. Ls Advsr Limited Liability stated it has 0% in CONMED Corporation (NASDAQ:CNMD). Northern Corporation has invested 0.01% of its portfolio in CONMED Corporation (NASDAQ:CNMD). Comerica Fincl Bank invested in 0.01% or 26,448 shares. Louisiana State Employees Retirement, Louisiana-based fund reported 10,000 shares. Pinnacle Associate Ltd has 0.01% invested in CONMED Corporation (NASDAQ:CNMD). Blackrock Advisors Limited Liability Company, Delaware-based fund reported 13,923 shares.

Since March 6, 2017, it had 4 insider purchases, and 2 insider sales for $347,557 activity. 440 CONMED Corporation (NASDAQ:CNMD) shares with value of $17,598 were bought by Cohen Heather L. Farkas Charles bought $7,994 worth of stock or 180 shares. Hartman Curt R had bought 8,030 shares worth $322,115. JONAS DANIEL sold $153,661 worth of stock or 3,000 shares. Kuyper Dirk had sold 1,000 shares worth $52,239 on Tuesday, June 13. On Monday, March 6 TRYNISKI MARK E bought $205,750 worth of CONMED Corporation (NASDAQ:CNMD) or 5,000 shares.

Analysts await CONMED Corporation (NASDAQ:CNMD) to report earnings on July, 26. They expect $0.42 earnings per share, down 10.64 % or $0.05 from last year’s $0.47 per share. CNMD’s profit will be $11.73M for 30.27 P/E if the $0.42 EPS becomes a reality. After $0.38 actual earnings per share reported by CONMED Corporation for the previous quarter, Wall Street now forecasts 10.53 % EPS growth. The stock increased 0.20% or $0.1 during the last trading session, reaching $50.85. About 75,914 shares traded. CONMED Corporation (NASDAQ:CNMD) has risen 27.59% since July 18, 2016 and is uptrending. It has outperformed by 10.89% the S&P500.

CONMED Corporation (NASDAQ:CNMD) Ratings Coverage

Among 4 analysts covering CONMED Corporation (NASDAQ:CNMD), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. CONMED Corporation had 9 analyst reports since July 22, 2015 according to SRatingsIntel. The company was downgraded on Wednesday, July 22 by Northland Capital. The rating was maintained by Needham with “Buy” on Friday, November 18. The stock of CONMED Corporation (NASDAQ:CNMD) has “Buy” rating given on Monday, October 12 by Ladenburg Thalmann. As per Thursday, April 28, the company rating was maintained by Needham. As per Monday, October 5, the company rating was maintained by Leerink Swann. The stock of CONMED Corporation (NASDAQ:CNMD) earned “Market Perform” rating by Northland Capital on Thursday, October 22. The company was maintained on Thursday, August 27 by Piper Jaffray.

CONMED Corporation is a medical technology company. The company has market cap of $1.42 billion. The Firm is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. It has a 115.03 P/E ratio. The Firm provides surgical devices and equipment for minimally invasive procedures.

More recent CONMED Corporation (NASDAQ:CNMD) news were published by: Reuters.com which released: “BRIEF-MedShape sells ExoShape ACL product line to CONMED Corp” on July 05, 2017. Also Businesswire.com published the news titled: “CONMED Corporation to Announce Second Quarter 2017 Financial Results on July …” on July 10, 2017. Prnewswire.com‘s news article titled: “MedShape Sells ExoShape┬« ACL Product Line to CONMED Corporation” with publication date: July 05, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: